semaglutide and heart failure In patients with cardiometabolic #HFpEF, #semaglutide #tirzepatide reduced the risk of hospitalization for or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide. #ESCCongress Semaglutide ameliorates pressure overload-induced cardiac

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information

When your fueling doesn't match your training volume, we see the same "red flags" across the board: The Biological Impact: If you are on a GLP-1, you cannot rely on "hunger" to tell you when to eat

Heres a quick breakdown of the key differences to help you decide

Key warning signs requiring urgent evaluation include: Postmenopausal bleeding (any vaginal bleeding occurring more than 12 months after the last menstrual period) Bleeding accompanied by fever, unusual vaginal discharge, or pelvic pain suggesting infection Bleeding associated with pregnancy or suspected pregnancy Recurrent spotting that persists for more than two to three menstrual cycles Patients taking tirzepatide who develop abnormal bleeding should undergo a comprehensive gynecological assessment, including detailed menstrual history, pelvic examination, and pregnancy testing for all reproductive-age women regardless of contraceptive use